{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:22:52Z","timestamp":1794601372883,"version":"4.9.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) therapies include both TTR gene silencers and TTR stabilizers. The role of TTR gene silencers added to background TTR stabilizer therapy is unknown, and the effects of silencer treatment in the absence of stabilizer use are unclear. In the CARDIO-TTRansform study, 1,432 patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009135 (9.4%) women and\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091,297 (90.6%) men) with ATTR-CM were randomized (1:1) and treated with the antisense oligonucleotide eplontersen (45\u2009mg every 4 weeks) that targets TTR or with placebo for up to 140 weeks. At baseline, 57% of the patients were taking TTR stabilizers. In the overall study, treatment with eplontersen did not reduce the primary composite endpoint. Here, in a prespecified analysis, we show that the primary endpoint (a composite of cardiovascular mortality and recurrent cardiovascular events) was modified by baseline stabilizer use (\n                    <jats:italic>P<\/jats:italic>\n                    <jats:sub>interaction<\/jats:sub>\n                    \u2009=\u20090.017). Benefits were observed in those patients not on stabilizers at baseline (rate ratio (RR)\u2009=\u20090.71, 95% confidence interval (CI) 0.54 to 0.93,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.012), whereas no benefits were observed in those on stabilizers at baseline (RR\u2009=\u20091.14, 95% CI 0.85 to 1.53,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.39). The safety profile of eplontersen was favorable, irrespective of baseline stabilizer use. Treatment with eplontersen versus placebo demonstrated a clinically meaningful benefit among patients not receiving background stabilizers but provided no additional clinical benefit in those on background stabilizer therapy. These findings of a strong treatment effect modification may offer insight for therapeutic decision-making in clinical practice. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04136171\" ext-link-type=\"uri\">NCT04136171<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04670-6","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:02:10Z","timestamp":1788091330000},"page":"4047-4055","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garc\u00eda-Pav\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot K.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-9232","authenticated-orcid":false,"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-700X","authenticated-orcid":false,"given":"Laura","family":"Obici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett W.","family":"Sperry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2011-8201","authenticated-orcid":false,"given":"Nobuhiro","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-2236","authenticated-orcid":false,"given":"M\u00e1rcia","family":"Waddington-Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Boman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A. M.","family":"Cuddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1196-3016","authenticated-orcid":false,"given":"Philippe","family":"Debonnaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nowell M.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Podolec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7834-3596","authenticated-orcid":false,"given":"Jersey","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-5008","authenticated-orcid":false,"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"4670_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0969-2126(97)00215-3","volume":"5","author":"JW Kelly","year":"1997","unstructured":"Kelly, J. W. Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure 5, 595\u2013600 (1997).","journal-title":"Structure"},{"key":"4670_CR2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg, F. L. et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 73, 2872\u20132891 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4670_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg, F. L. & Maurer, M. S. Cardiac amyloidosis due to transthyretin protein: a review. JAMA 331, 778\u2013791 (2024).","journal-title":"JAMA"},{"key":"4670_CR4","doi-asserted-by":"publisher","first-page":"112270","DOI":"10.5493\/wjem.v16.i1.112270","volume":"16","author":"M Bouziane","year":"2026","unstructured":"Bouziane, M., Moufid, O. & Habbal, R. Cardiac amyloidosis: from diagnosis to therapeutics breakthroughs. World J. Exp. Med. 16, 112270 (2026).","journal-title":"World J. Exp. Med."},{"key":"4670_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane, T. et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140, 16\u201326 (2019).","journal-title":"Circulation"},{"key":"4670_CR6","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s11136-024-03723-y","volume":"33","author":"M Poledniczek","year":"2024","unstructured":"Poledniczek, M. et al. Health-related quality of life is an independent predictor of mortality and hospitalisations in transthyretin amyloid cardiomyopathy: a prospective cohort study. Qual. Life Res. 33, 2743\u20132753 (2024).","journal-title":"Qual. Life Res."},{"key":"4670_CR7","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ehf2.15147","volume":"12","author":"R Willixhofer","year":"2025","unstructured":"Willixhofer, R. et al. Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing\u2014a multicentre study. ESC Heart Fail. 12, 1326\u20131335 (2025).","journal-title":"ESC Heart Fail."},{"key":"4670_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cardfail.2024.06.003","volume":"31","author":"P Garcia-Pavia","year":"2025","unstructured":"Garcia-Pavia, P. et al. Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). J. Card. Fail. 31, 525\u2013533 (2025).","journal-title":"J. Card. Fail."},{"key":"4670_CR9","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore, J. D. et al. A new staging system for cardiac transthyretin amyloidosis. Eur. Heart J. 39, 2799\u20132806 (2018).","journal-title":"Eur. Heart J."},{"key":"4670_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007\u20131016 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4670_CR11","unstructured":"US Food & Drug Administration. Tafamidis Prescribing Information https:\/\/www.fda.gov\/media\/126283\/download (2019)."},{"key":"4670_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore, J. D. et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 390, 132\u2013142 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4670_CR13","unstructured":"US Food and Drug Administration. Acoramidis Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216540s000lbl.pdf (2024)."},{"key":"4670_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana, M. et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N. Engl. J. Med. 392, 33\u201344 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4670_CR15","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho, T. et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 330, 1448\u20131458 (2023).","journal-title":"JAMA"},{"key":"4670_CR16","doi-asserted-by":"publisher","unstructured":"Fontana, M. et al. Eplontersen for transthyretin amyloid cardiomyopathy. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2608510 (2026).","DOI":"10.1056\/NEJMoa2608510"},{"key":"4670_CR17","doi-asserted-by":"publisher","first-page":"E6741","DOI":"10.1073\/pnas.1805131115","volume":"115","author":"L Saelices","year":"2018","unstructured":"Saelices, L. et al. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. Proc. Natl Acad. Sci. USA 115, E6741\u2013E6750 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4670_CR18","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s10741-022-10237-7","volume":"27","author":"P Morfino","year":"2022","unstructured":"Morfino, P. et al. Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. Heart Fail. Rev. 27, 2187\u20132200 (2022).","journal-title":"Heart Fail. Rev."},{"key":"4670_CR19","doi-asserted-by":"publisher","unstructured":"Fontana, M. et al. Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in the CARDIO-TTRansform trial of eplontersen. Eur. J. Heart Fail. https:\/\/doi.org\/10.1093\/ejhf\/xuag168 (2026).","DOI":"10.1093\/ejhf\/xuag168"},{"key":"4670_CR20","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.jacc.2025.04.008","volume":"85","author":"RM Witteles","year":"2025","unstructured":"Witteles, R. M. et al. Vutrisiran improves survival and reduces cardiovascular events in ATTR amyloid cardiomyopathy: HELIOS-B. J. Am. Coll. Cardiol. 85, 1959\u20131970 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"4670_CR21","doi-asserted-by":"publisher","first-page":"e014205","DOI":"10.1161\/CIRCHEARTFAILURE.126.014205","volume":"19","author":"A Masri","year":"2026","unstructured":"Masri, A. et al. Rationale and design of CARDIO-TTRansform, a phase 3 trial of eplontersen in transthyretin amyloid cardiomyopathy. Circ. Heart Fail. 19, e014205 (2026).","journal-title":"Circ. Heart Fail."},{"key":"4670_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/1467-9868.00259","volume":"62","author":"DY Lin","year":"2000","unstructured":"Lin, D. Y. et al. Semiparametric regression for the mean and rate functions of recurrent events. J. R. Stat. Soc. B 62, 711\u2013730 (2000).","journal-title":"J. R. Stat. Soc. B"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04670-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04670-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04670-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T19:49:34Z","timestamp":1794599374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04670-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4670"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04670-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]},"assertion":[{"value":"20 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.G.-P. reports speaking fees from Alnylam Pharmaceuticals, AstraZeneca, Bayer, BridgeBio, Intellia, Ionis Pharmaceuticals, Novo Nordisk and Pfizer; consulting fees from Alexion, Alnylam Pharmaceuticals, AstraZeneca, Attralus, Bayer, BridgeBio, Idoven, Intellia, Immutrin, Ionis Pharmaceuticals, Life Molecular Imaging, Pfizer, Neuroimmune and Novo Nordisk; and research\/educational support for their institution from Alnylam Pharmaceuticals, AstraZeneca, Bayer, BridgeBio, Idoven, Intellia, Novo Nordisk and Pfizer. F.C. reports participation on advisory councils or committees for Pfizer, Alnylam, AstraZeneca, Bayer, BridgeBio and Novo Nordisk. M.K.D. reports honoraria from AstraZeneca, Alnylam, Novo Nordisk, Pfizer and Intellia; consulting fees from AstraZeneca, Alnylam, Novo Nordisk and Pfizer; and grants or funds from Pfizer. M.F. reports consultancy for Alnylam, Alexion\/Caelum Biosciences, AstraZeneca, BridgeBio\/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium and Neuroimmune; research grants from Alnylam, BridgeBio, AstraZeneca, Pfizer and British Heart Foundation; and share options in Lexeo Therapeutics and shares in Mycardium and Immutrin. J.D.G. reports consulting fees from Alnylam, AstraZeneca, Attralus, Alexion, Bayer, BridgeBio, Intellia, Ionis and Pfizer; and grants or funds from Alnylam and AstraZeneca. M.H. reports consulting fees from Pfizer, AstraZeneca, Alexion, BridgeBio, Alnylam and Novo Nordisk. A.M. reports consulting fees from Cytokinetics, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity and Neuroimmune; and grants or funding from Pfizer, Attralus, Cytokinetics and Janssen. L.O. reports honoraria and consulting fees from AstraZeneca, Alnylam, Bayer, Intellia, Purpose Pharma, Novo Nordisk and Pfizer. S.D.S. reports consulting fees from Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi Sankyo, GSK, Lilly, Merck, MyoKardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi Pasteur, DiNAQOR, Tremeau, CellProthera, Moderna, American Regent, Sarepta, Lexicon, AnaCardio, Akros and Valo; and grants or funding from Alexion, Alnylam, AstraZeneca, Bellerophon, Bayer, BMS, Cytokinetics, Eidos, Gossamer, GSK, Ionis, Lilly, MyoKardia, NIH\/NHLBI, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Theracos and US2.AI. B.W.S. reports participation on advisory councils or committees and receiving honoraria from Alnylam, BridgeBio, AstraZeneca and Pfizer. N.T. reports participation on advisory councils or committees for AstraZeneca; honoraria from Pfizer, Alexion, Alnylam and AstraZeneca; and reimbursement for attending symposia from Pfizer, Alexion, Alnylam and AstraZeneca. M.W.-C. reports participation on advisory councils or committees and receiving consulting fees from AstraZeneca. K.B. reports participation on advisory councils or committees for Alnylam; grants or funding from FAMY (Italian Familial Amyloidosis Association), honoraria for lectures and educational webcasts from AstraZeneca, Pfizer and Add Health Media, and HeartLung associations in Sweden; and has received consulting fees from Alnylam, Pfizer and AstraZeneca. S.A.M.C. reports participation on advisory councils or committees for Alnylam, AstraZeneca, Alexion, Novo Nordisk, BridgeBio, Intellia and Pfizer; honoraria from Bayer, AstraZeneca, Alnylam, Novo Nordisk and Pfizer; consulting fees from Life Molecular Imaging; and grants or funds from NIH (1K23HL166686) and AHA (23CDA857664). P.D. reports participation on advisory councils or committees for Pfizer, AstraZeneca, Bayer and Alnylam; reimbursement for attending symposia from Bayer; consulting fees from Pfizer, AstraZeneca, Bayer and Alnylam; and grants or funds from Pfizer and AstraZeneca. N.M.F. reports consulting fees from Alnylam, AstraZeneca, Alexion, BridgeBio, Intellia, Janssen, Novo Nordisk, Pfizer and Sanofi; and grants or funds from Alnylam, AstraZeneca, Alexion, BridgeBio, Intellia, Janssen, Novo Nordisk and Pfizer. P.P. reports honoraria for educational lectures from Pfizer, Sandoz, BMS, Sanofi and Servier. A.Y. performed consultant activities for Alnylam, AstraZeneca, Bayer, Alexion, Pfizer, Bristol Myers Squibb, Cytokinetics, Novo Nordisk and GE Healthcare; and has research collaborations with Philips and Circle Cardiovascular Imaging. T.C. is a current employee of AstraZeneca. Q.Y. is a current employee of Ionis Pharmaceuticals and reports owning Ionis Pharmaceuticals stock. B.L.C. reports consulting fees from Alnylam, Bristol Myers Squibb, Cardior, Cardurion, Corvia, CVRx, Eli Lilly, Intellia, Rocket and Valo; and has served on a data safety monitoring board for Novo Nordisk. J.C. is a current employee of and owns shares in AstraZeneca. S.T. is a current employee of and owns shares in Ionis Pharmaceuticals. M.S.M. reports participation on advisory councils or committees for Alnylam, Ionis, AstraZeneca, Pfizer, BridgeBio, Bayer, Attralus, Alexion, Novo Nordisk and Intellia; reimbursement for attending symposia from Intellia and Pfizer; consulting fees from Alnylam, Ionis, AstraZeneca, Pfizer, BridgeBio, Bayer, Alexion, Novo Nordisk and Intellia; and grants or funds from BridgeBio.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}